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Supplementary Material 
Supplementary methods 
Treatment trials and other studies of tocilizumab 
We restricted the main analysis to RCTs comparing tocilizumab treatment (4mg/kg or 8mg/kg) with placebo, 
with or without background treatment using other anti-inflammatory or immunosuppressive interventions. We 
also investigated the association between tocilizumab treatment and CRP concentration in non-randomised 
cohort studies. 
 
Genetic studies 
Study characteristics of genetic studies included in the analysis are detailed in Supplementary table 1 . The 
studies from which individual participant data were included in the present analyses are listed below, and 
include 26 prospective studies, four randomised cardiovascular prevention trials, two cross-sectional studies, 
eight retrospective case-control studies. 
 
Prospective cohort studies 
Twenty-five prospective studies contributed genotypic and phenotypic data, and their design is described 
elsewhere.  
From the UCL-LSHTM-Edinburgh-Bristol (UCLEB) Consortium:  
British Regional Heart Study (BRHS)1, the British Women's Heart and Health Study (BWHHS)2, the Caerphilly 
Prospective Study (CaPS)3, the Edinburgh Artery Study (EAS)4, the English Longitudinal Study of Aging 
(ELSA)5, the Edinburgh Type 2 Diabetes Study (ET2DS)6, the Northwick Park Heart Study II (NPHS-II)7, the 
Whitehall-II (WHII) study8, and the MRC National Study of Health and Development (1946 Birth Cohort, MRC 
NSHD)9. 
 
From the National Heart, Lung and Blood Institute (NHLBI) Candidate Gene Association Resource (CARe) 
Consortium10: the Atherosclerosis Risk in Communities Study (ARIC)11, the Coronary Artery Risk 
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 Development in Young Adults (CARDIA)12, the Cleveland Family Study (CFS)13,14, the Cardiovascular Health 
Study (CHS)15, the Framingham Heart Study (FHS)16, and the Multi-Ethnic Study of Atherosclerosis 
(MESA)17. 
 
From the Health, Alcohol and Psychosocial factors In Eastern Europe (HAPIEE) study18: the Czech Republic 
(HAPIEE-CZ), Lithuania (HAPIEE-LT), Poland (HAPIEE-PL) and Russia (HAPIEE-RU) arms of the study. 
 
Also, the MRC Ely Cohort19(40), the MRC Fenland Cohort (2 samples) 20, the IMPROVE study21, the 
Prevention of Renal and Vascular Endstage Disease study (PREVEND)22, the Second Manifestations of 
Arterial Disease (SMART) Study23, the InCHIANTI study24 and the MedStar study25. 
 
Three RCT studies were included - the Aspirin in Asymptomatic Atherosclerosis (AAA) trial26, the PROSPER 
trial follow-up study27, and the Thrombosis Prevention Trial follow-up study (TPT)28. These trials were treated 
as prospective cohorts for the purposes of these analyses. 
 
Case-control, case-cohort and cross-sectional studies 
Four nested case-control studies were included - the EPIC-Netherlands study (EPIC-NL)29, the EPIC-Norfolk 
study (EPIC-N, case-cohort design)30, the Utrecht Cardiovascular Pharmacogenetics study (UCP)31 and the 
Women's Health Initiative (WHI)32.  
 
Two cross-sectional studies of diabetes were included - the Ealing Diabetes Study (EDS)33 and the UCL 
Diabetes and Cardiovascular Study (UDACS)34.  
Four case-control and case-cohort studies contributed data: i) the Hypercoagulability and Impaired Fibrinolytic 
function Mechanisms (HIFMECH) study35 included recent survivors of first myocardial infarction (MI) and age-
matched healthy control; 
ii) The Ischemic Stroke Genetics Study-Siblings With Ischaemic Stroke (ISGS-SWISS) consortium, a case-
control GWAS study of ischaemic stroke36,37;  
iii) the Colorectal Tumour Gene Identification study (CORGI) 38; and  
iv) the Colorectal Cancer Genetics Study (COGS) - both GWA studies, contributed data on colorectal cancer. 
Further details of these studies are given in Supplementary table 1. 
2
  
Genome-wide association studies and other cohorts contributing published, summary data 
Thirteen published GWA studies contributed look-up data to the analyses. The GerMIFS II study39, the 
INTERHEART study40, the ISIS study41,42, the LOLIPOP study43, the PROCARDIS study44, the Wellcome 
Trust Case-Control Collaboration45, the British Breast Cancer Study46, the Cancer Genetic Markers of 
Susceptibility study47, the Nurses' Health Study, the National Cancer Research Network, Mammography, 
Oestrogens and Growth Factors study, the Colorectal Tumour Gene Identification study (CORGI) 38, and the 
MRC British 1958 Birth Cohort48 contributed 13574 aggregated breast cancer cases and 14852 controls49.  
 
Phenotypic measures 
Demographic, anthropometric and biomarker variables 
Blood lipid fractions evaluated as primary biomarker outcomes were total, LDL- and HDL-cholesterol and 
triglycerides. Availability of data for biomarkers in the primary analysis is detailed in Supplementary Table 2. 
All biomarkers were measured using validated assays and protocols reported previously. Biomarker 
measurements were taken from either the baseline phase of each study or from the next phase soonest after 
baseline at which data on the greatest number of biomarkers were available. Where key biomarkers were 
unavailable at the principal survey phase their data were included from the chronologically closest available 
phase. Continuous variables that were not normally distributed were loge transformed to achieve normality, and 
all biomarkers were converted to common units of measurement. Levels of LDL were not measured directly in 
some studies (HAPIEE-RU and CaPS) and were therefore calculated from data on total and HDL-cholesterol 
and triglyceride levels using the Friedewald formula50. 
Where data for LDL-, HDL- and total cholesterol were available in units of mg/dL, they were converted to 
mmol/L using a multiplication factor of 0.02586. Triglyceride units were similarly converted using a factor of 
0.01129.  
We also estimated IL6R SNP associations with haemoglobin, platelet count and hepatic enzyme levels that have 
also been reported to be altered by tocilizumab treatment9,10,24–26. 
 
Clinical outcome reporting 
Since event definitions differed between collaborating studies, common definitions were set to accommodate 
data from as many cohorts as possible. Several studies reported validated events (using case-note data or 
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 similar), but others recorded only self-reported events. We included all events in the analysis - self-reported and 
validated - since self-reported data was the lowest common denominator between studies (Supplementary 
Table 3). Where possible, only validated self-reported events were included. The primary outcome (all fatal 
and non-fatal CHD events) included acute myocardial infarction (MI), coronary artery bypass grafting or other 
coronary revascularisation, but not angina pectoris. Where World Health Organisation International 
Classification of Disease (ICD) codes were available, fatal CHD events included ICD-10 codes I-21, I-22, I-23, 
I-24 and I-25, and ICD-9 codes 410.0 to 410.9. Stroke of all aetiology (including haemorrhagic and ischaemic 
events)was included. Fatal stroke events included ICD-10 codes I-61 to I-64, I-67 and I-69, and ICD-9 codes 
430.0 to 434.9. 
 
Where data allowed, only the first recorded cardiovascular event (of any type) was included and all subsequent 
events excluded from the analysis. Prevalent events were defined as those occurring prior to study baseline and 
incident events as any event occurring during follow-up. 
 
SNP selection 
We aimed to compile the smallest set of variants to yield the most data on effects of IL6R genotype and 
therefore act as the most robust instruments for variation in the gene. A number of open-access populations of 
European ancestry were searched via the Genome Variation Server and the International HapMap Project 
(Release 23a/Phase 3)51 for SNP within and 20kbp up- and downstream of IL6R. Using HaploView52 and 
existing genotype data from Whitehall II we identified tagging SNPs present on the IBC HumanCVD BeadChip 
v2 (Cardiochip). SNPs were included on the HumanCVD BeadChip (Cardiochip) platform array  - a candidate 
gene-based SNP array including a high density of markers in  nearly 2,000 genes implicated in CVD - in part for 
their ability to tag genetic variation at this locus. Of those included on Cardiochip, we excluded SNPs whose 
associated p-value for univariate linear regression of circulating loge IL-6 levels on genotype conducted using 
PLINK in Whitehall II participants was greater than p=1x10-5 in an additive model. For each SNP we also 
assessed the beta-coefficient for the above linear regression model and the minor allele frequency in Whitehall 
II and the HapMap CEU samples. Using data from the 1000 Genomes Project Pilot 1, we evaluated linkage 
disequilibrium (LD) between each of the resulting shortlisted SNPs and between those and SNPs identified by 
previous genome-wide association studies of quantitative traits, giving preference to SNPs capturing data for 
previously identified SNPs or multiple IL-6-associated SNPs in Whitehall II. Where possible we excluded SNPs 
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 in strong LD (r2>0.9) to assemble the final subset of SNPs for genotyping across the collaborating studies. The 
consequence and function of each selected SNP was assessed using HapMap, NCBI SNP database 
(http://www.ncbi.gov.uk/snp), Ensembl (http://www.ensembl.org), UCSC Genome Browser53. 
 
Genotyping and genotype data quality control 
Genotypes were coded as 0, 1 or 2 homozygous common allele, heterozygous and homozygous minor allele 
respectively.  
We included existing genotype data where available and commissioned new genotyping where necessary.  
Studies used a variety of genotyping platforms including: the ITMAT/Broad Institute CARe Consortium 
HumanCVD BeadChip (‘Cardiochip’)54; Illumina Metabochip, Illumina 550k v1/3 and 610/660K (Illumina, 
San Diego CA, USA); Affymetrix GeneChip Human Mapping 500K and Affymetrix Genome-Wide Human 
SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA); the ABI TaqMan (Applied Biosystems, Foster City, CA, 
USA); or KASPar (KBiosciences, Hoddesdon, UK) [add other collaborator platforms].  
 
Statistical analysis 
Participant inclusion criteria 
We restricted the analysis to unrelated individuals with available data for genotype at the lead SNP (or one of its 
proxies), and for at least one biomarker or clinical outcome. 
 
Relatedness  
Where study family structure was recorded, in each group of related participants all but the eldest of the group 
were excluded from the analyses. 
 
SNP associations with continuous risk factors and circulating biomarkers 
Analyses were based on an additive genetic model justified on the basis of the association of the three IL6R 
SNPs including rs7529229 (the most widely typed of these SNPs across all studies) with the circulating 
concentration of IL-6. Weighted mean difference between genotypes was calculated using the 'metan' command 
in Stata v 11.2, applying inverse-variance weighted fixed effects meta-analysis to the mean of each biomarker 
by genotype. Using the common homozygous group as a reference, the difference between the reference and 
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 heterozygous and rare homozygous groups was estimated. Where biomarkers were loge transformed, the 
proportional difference between geometric means was calculated. Linear regression models (using the 'regress' 
command in Stata and equivalent procedures in other analysis packages) were used to estimate differences (and 
95% confidence intervals, CI) in biomarkers per additional minor allele possessed at each SNP. For biomarkers 
that had been loge transformed, the beta-coefficient from such a regression model was exponentiated to find the 
proportional difference in geometric means associated with possession of each additional minor allele. Within 
study estimates of per-allele effects were combined using Mantel-Haenszel fixed effects meta-analysis. 
 
Subgroup analyses 
SNP associations with continuous biomarkers and with clinical outcomes were analysed with stratification by 
the following subgroups: males, females, individuals aged <55 years, 56-65 years and >65 years; individuals 
with and without CVD at the time of biomarker measurement; those with and without type-2 diabetes mellitus; 
users and non-users of lipid-lowering drugs; individuals with 10 year Framingham CHD risk of above and 
below 20%; individuals stratified by tertiles of non-HDL-cholesterol; body mass index <25kg/m2, 25-30kg/m2 
and >30kg/m2; genotyping platforms and study designs. Tests of interaction between subgroups were performed 
using the chi-squared test for heterogeneity within the 'metan' command in Stata. 
 
SNP associations with clinical outcomes 
We estimated for each disease endpoint the odds ratio (OR) and 95% CI per minor allele for each SNP 
(rs7529229, rs4845371, rs12740969) under an additive model, as above, where data were available. Per-allele 
odds ratios were calculated by logistic regression models (using the 'logit' command in Stata) and resulting odds 
ratios combined using inverse-variance weighted fixed effects meta-analysis to derive a summary estimate (the 
'metan' command in Stata v11.1). These analyses included only studies where at least one case and one control 
for the relevant outcome were available. Sensitivity analysis using different genetic models (heterozygous vs. 
common allele homozygous, and minor allele homozygous vs. common allele homozygous) were also 
conducted (data available on request). 
In studies where all participants were diabetic, individuals free of diabetes from EAS were used as controls for 
ET2DS and from Whitehall-II for EDSC and UDACS when calculating odds ratios by logistic regression with 
type 2 diabetes as the outcome.  
 
6
 Systematic review of treatment trials and other investigations of tocilizumab  
Search strategy 
We searched PubMed on 7 September 2010 using the keyword “tocilizumab” and supplemented this by a search 
of reference lists of existing reviews and a systematic review of tocilizumab treatment published by the 
Cochrane Collaboration55. 
Data extraction and analysis 
Data were extracted by MVH and information extracted from a random selection of eligible studies was 
checked by DIS. CRP was selected as a biomarker by which the magnitude of tocilizumab's treatment effect 
could be indexed since it was the most widely reported at the greatest number of treatment doses and time-
points for which data were available in the genetic studies. For continuous variables other than CRP, the 
difference from baseline in the active arm was compared to the difference in baseline of placebo for 8mg/kg vs. 
placebo RCT only. The most parsimonious time-points were chosen to maximise data yield across studies and 
also to prevent studies from being represented twice. For CRP, values were extracted for RCTs and cohort 
studies investigating 4mg/kg, 8mg/kg or 16mg/kg TCZ versus placebo at 8-12 weeks following initial 
treatment. For RCT, the difference in CRP from baseline in the intervention arm was compared to that of the 
difference in the placebo group. For cohort studies, only the difference between baseline and follow-up was 
compared (as there was no comparator arm). We abstracted data for all clinically relevant biomarkers and safety 
endpoints. Trial results were combined with Mantel-Haenszel (binary traits) and inverse variance (continuous 
traits) fixed effects meta-analysis performed using Stata 11.2 (StataCorp, Texas, USA). 
 
  
7
 Supplementary results 
 
IL-6, CRP, fibrinogen and blood lipid concentrations 
Four studies were conducted exclusively in men (BRHS, CaPS, HIFMECH, and NPHS-II) and two exclusively 
in women (BWHHS and WHI), all remaining studies contributed participants from both genders (with the 
proportion of men in the range 18% and 75%).  
 
Study-specific geometric mean concentrations (approximate SD) were in the range 1.01 (0.66) to 3.49 
(2.48)pg/ml for IL-6 (17 studies, 29,978 individuals), 0.85 (0.99) to 3.10 (3.49) mg/L for CRP (31 studies, 
77,290 individuals) and 1.99 (0.44)g/L to 3.57 (0.77)g/L for fibrinogen (19 studies, 53,480 individuals). Total 
cholesterol concentration, available in 35 studies (n=119,565) was in the range (mean, SD) 3.71 (1.93) to 7.06 
(1.33) mmol/L; LDL-C, available in 30 studies (n=102,107) was in the range 2.19 (1.24) to 4.93 (1.17) mmol/L; 
HDL-C, available in 32 studies (n=109,688) was in the range 0.84 (0.26) to 1.68 (0.52) mmol/L; non-HDL-C 
available in 30 studies (n=100,762) was in the range 3.02 (0.87) to 5.61 (1.30) mmol/L; and triglycerides, 
available in 32 studies (n=109,926) was in the range (geometric mean, approximate SD) 0.76 (0.38) to 4.71 
(3.35) mmol/L (Supplementary Figure 5). 
 
SNP selection, quality control & genotype 
The Genome Variation Server identified 44 SNPs and the HapMap database 67 SNPs in the region of IL6R, of 
which 26 and 24 respectively passed the MAF threshold of 30%. Of the HapMap variants, 13 were designated 
tagging SNPs. Of the 42 SNPs in IL6R included on the CardioChip, 12 met the p-value threshold of p<1x10-5 for 
association with circulating loge IL-6 at phase 3 of the Whitehall II study. Strong linkage disequilibrium (r2>0.9) 
was noted between one of the CardioChip SNPs and SNPs identified by GWAS studies for C-reactive protein56 
and soluble IL-6 receptor57. Evaluation of effect size (indicated by linear regression beta-coefficient and R2 
values) and linkage disequilibrium between SNPs around the IL6R gene (Supplementary figure 3) suggested 
an ultimate subset of 3 SNPs. Of these, 2 (rs7529229 and rs4845371) were located within IL6R itself and one 
(rs12740969) in TDRD10, 34kbp from IL6R. The latter SNP was selected because it captured information on 
variation at the 3' end of IL6R. Carriage of the minor allele at rs7529229 resulted in higher circulating levels of 
IL-6, whilst the minor alleles at rs4845371 and rs12740969 were associated with lower IL-6 levels.  
Association of additional IL6R SNPs with inflammatory biomarkers 
8
 The ass ociations o f t he o ther IL6R S NPs ( rs4845371, rs12 740969) with IL- 6, CRP  and fibrinogen w ere 
consistent with but opposite in direction to the findings for the rs7529229 variant (Supplementary figure 8). 
 
 
Reporting of IL6R variants associated with safety endpoints. 
The NHGRI cat alogue of genome-wide association studies lists 8 G WA studies of colorectal cancer (searched 
14 A pril 2011) and 12 GWA st udies of prostate c ancer (sea rched 18 Ap ril 2011) of w hich none rep orted 
variants in IL6R in either main or supplementary results.  Of the 16 GWA studies of breast cancer (searched 15 
April 2011), one study reported SNPs in IL6R though there was no association of those with cancer 58 (Figure 
4). 
 
Association of IL6R variants with CHD events 
Estimates for the association of the IL6R variant with risk of CHD were consistent between the present de novo 
analysis and previously published case-control study data for the rs4537545 variant in LD (r2=1.0 in the 
HapMap CEU sample) with rs7529229 1 (Figure 3).  
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3 - Clinical event definitions 
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 Supplementary Table 1 - Collaborating study characteristics   
Study name Study design Geographical location Sampling frame Participants included Baseline year(s) % Male Age (Mean ,SD) 
Present genetic analysis  
AAA RCT  UK General practice 2,359 1998-2001 29 61.9 (6.6) 
ARIC  Cohort  USA Community    9,588 1986 47 54.3 (2.7) 
BRHS  Cohort UK General practice 3,945 1978-1980 100 68.7 (5.5) 
BWHHS  Cohort UK General practice 3,445 1999-2001 0 69.4 (5.5) 
CARDIA  Cohort  USA Community 1,443 1984 47 25.6 (3.4) 
CaPS Cohort UK Community 1404 1984-1988 100 56.7 (4.4) 
CFS  Cohort  USA Community (family) 135 1995 59 53.9 (14.7) 
CHS  Cohort  USA Community 3,952 1989 45 70.4 (5.3) 
COGS Case-control UK Clinic 1905 n/a 47 n/a 
CORGI Case-control UK Population 1978 n/a 51 51.0 (5.9)* 
EAS  Cohort UK General practices 917 1987 51 64.3 (5.6) 
EDS Cross-sectional UK Diabetes clinic 319 2001-2003 61 63.7 (13.7) 
ELSA  Cohort UK HSE respondents 5,504 1998, 1999, 2001 46 61.0 (9.6) 
Ely  Cohort UK General practice 1,601 1990-1992 47 61.1 (9.2) 
EPIC-N Nested C-Ct UK Community 1,690 1993-1997 50 60.1 (9.0) 
EPIC-NL   Nested C-Ct Netherlands Existing cohorts 5,194 1993-1997 22 54.1 (10.1) 
ET2DS  Cohort UK Community (cases) 1,069 2006-7 51 67.9 (4.2) 
FHS  Cohort  USA Community 1,336 1948/1971/2002 47 45.7 (10.1) 
HAPIEE-CZ Cohort Czech Republic Population 6,685 2002-2005 47 58.3 (7.1) 
HAPIEE-LT Cohort Lithuania Population 6,887 2002-2005 45 61.0 (7.6) 
HAPIEE-PL Cohort Poland Population 8,716 2002-2005 49 57.7 (7.0) 
HAPIEE-RU Cohort Russia Population 7,082 2002-2005 46 58.9 (7.1) 
HIFMECH Case-control Europe Cases/community 1,096 n/a 100 51.7 (5.5) 
IMPROVE  Cohort Europe Clinic 3,465 2003 48 64.2 (5.4) 
InCHIANTI Cohort Italy Community 1,199 1998 44.8 68.4 (0.5) 
ISGS-SWISS Case-control USA Hospital/community 2,558 2001 52 66.1 (13.7) 
MedStar  Cohort USA Clinic 866 2004-7 67 53.5 (10.2) 
MESA  Cohort  USA Community 2,298 2000 48 65.7 (10.2) 
MRC Fenland - GWAS†  Cohort UK General practices 1,376 2004 (ongoing) 44 45.0 (7.3) 
MRC Fenland - Metabochip†  Cohort UK General practices 3,059 2004 (ongoing) 47 47.0 (7.1) 
MRC NSHD Birth cohort UK Birth register 2,402 1946 53 53 (0) 
NPHS-II  Cohort UK General practices 2,755 1989-1994 100 56.6 (3.4) 
PREVEND RCT Netherlands Community 3,867 1997 51 49.6 (12.5) 
PROSPER RCT  Europe Clinic 5,244 1997-1999 48 75.3 (3.4) 
SMART Cohort Netherlands Clinic 8,026 1996 68 56.5 (12.4) 
TPT RCT UK General practice 5,085 1984-1989 100 57.4 (6.7) 
UCP Nested C-C Netherlands Clinic 1,632 2007 75 62.8 (9.6) 
UDACS Cross-sectional UK Diabetes clinic 585 2001-2002 59 66.7 (11.0) 
WHI Nested C-C  USA Community 5,723 1994-1998 0  67.8 (6.7) 
Whitehall II  Cohort UK Workplace 5,059 1985-1988 74 49.2 (6.0) 
 
Published data  
GerMIFS II Case-control Germany Clinic 2,520 n/a NR NR 
INTERHEART E Case-control International Clinic 1,691 n/a NR NR 
ISIS Case-control International Clinic 3,566 n/a NR NR 
11
 LOLIPOP E Cohort UK Community 6,657 n/a NR NR 
PROCARDIS Case-control UK Clinic 8,328 n/a NR NR 
WTCCC Case-control UK Clinic 4,863 n/a NR NR 
 
Footnote: 
All cohort studies were prospective 
The MRC Fenland Study is a single cohort though was genotyped using two platforms with different individuals in each group and therefore is reported as two distinct 
samples here. 
C-C : case-control; C-Ct: case-cohort; HSE - Health Survey for England 
*Mean age in controls 
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 Supplementary Table 2 - Data availability for biomarkers & events in studies contributing to the primary genetic analysis  
Circulating biomarkers Clinical events (prevalent & incident) 
IL-6 CRP Fibrinogen TC HDL-C LDL-C Non-HDL-C CHD events Stroke Diabetes 
AAA -  1,926   2,064   2,260  - - - 95 48 48 
ARIC  299   7,583   9,495   9,569   9,571   9,414   9,569  1,837 522 1,184 
BRHS  2,261   3,863   3,865   3,853   3,742   3,761   3,739  668 424 289 
BWHHS  3,257   3,162   3,258   3,257   3,253   3,177   3,253  655 252 458 
CARDIA  226   1,315   681   1,435   1,435   1,435   1,435  10 4 99 
CaPS  782   949   942   1,337   1,298   1,337   1,337  281 132 119 
CFS  39   39   36   39   39   38   39  16 13 17 
CHS  3,635   3,923   3,917   3,942   3,937  -  3,937  128 551 - 
EAS  632   654   871   889   884   884   884  312 123 31 
EDS -  79  -  305   284   265   281  51 22 319 
ELSA -  5,433   5,401   5,436   5,434   5,292   5,434  - - - 
Ely -  624  -  1,600   1,598   1,597   1,598  - - - 
EPIC-N - - - - - - - - - 727 
EPIC-NL -  4,343  -  4,343   3,586   4,267   3,066  1,303 553 1,112 
ET2DS  1,031   1,017   1,030   1,025   1,025    1,025  145 60 1,053 
FHS  766   314   310   848   847   847   847  159 64 161 
HAPIEE-CZ -  6,486  -  6,546   6,522   6,278   6,521  435 291 351 
HAPIEE-LT -  915  -  6,872   6,754   6,689   6,754  376 394 394 
HAPIEE-PL -  900  -  8,751   8,750   8,615   8,750  737 206 657 
HAPIEE-RU -  1,019  -  7,083   7,081   7,079   7,081  648 462 255 
HIFMECH  779   1,017   988   1,013  - - - 509 3 59 
IMPROVE -  3,463  -  3,459   3,459   3,398   3,459  301 63 858 
InCHIANTI 1,199 - - - - - - - - - 
ISGS-SWISS - - - - - - - - 1,070 - 
MedStar - - - - - - - 421 - - 
MESA  2,256   2,289   2,288   2,293   2,291   2,261   2,291  100 32 220 
MRC Fenland GWAS  -  1,328  -  1,373   1,373   1,364   1,373  - - - 
MRC Fenland Metabochip - - -  3,052   3,052   3,027   3,052  - - - 
MRC NSHD - - -  2,236   2,082   2,072   2,082  - - - 
NPHS-II -  2,210   2,653   2,646   1,776   1,678   1,763  269 66 269 
PREVEND -  3,664  -  3,842   3,784   3,702   3,763  289 34 147 
PROSPER  5,129   5,154   5,103   5,243   5,242   5,241   5,242  589 241 807 
13
  
 
 
 
 
 
 
 
 
Abbreviations: TC - total cholesterol; HDL-C - high density lipoprotein cholesterol; LDL-C - low density lipoprotein cholesterol 
 
  
SMART - 4,465 - 7,979 7,973 7,535 7,971 - - - 
TPT - -  3,692   3,740  - - - 299 72 - 
UCP - - - - - - - 632 - - 
UDACS  574   570  -  582   582   565   582  60 39 585 
WHI  4,472   4,495   4,458   4,743   4,728   4,661   4,728  2,396 1,076 281 
Whitehall II  2,501   3,328   1,615   3,014   3,018   1,526   2,954  418 114 336 
Total 29,978  77,290  53,480  119,565 109,688  102,107 100,762    
14
 Supplementary Table 3 - Clinical event definitions  
 Prevalent CVD 
events 
All CVD events (prevalent & 
incident) 
All CHD events (prevalent & 
incident) 
All stroke (all aetiology, prevalent & 
incident) 
Diabetes (all aetiology, prevalent & 
incident) 
 Non-fatal  Non-fatal Fatal Non-fatal Fatal Non-fatal Fatal Non-fatal Fatal 
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AAA ●  ● ● ● ● ● ● ● ● ● ● ● ● ● 
ARIC ●  ● ● ● ● ● ● ● ● ● ● ● ● ● 
BRHS ●  ● ● ● ● ● ● ● ● ● ●   
BWHHS ●  ● ● ● ● ● ● ● ● ● ● ● ● ● ● - - 
CaPS ● ●  ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
CARDIA ●  ● ●  ● ●  ● ●  ● ●  
CFS ●    ●   ●    ●    ●   
CHS ●   ●    ●    ●    ●    
EAS ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●  ● ● 
EDS - - - ● ● - - ● ● - - ● ● - - ● ● - - 
ELSA - - - - - - - - - - - - - - - - - - - - - - - 
Ely - - - - - - - - - - - - - - - - - - - - - - - 
EPIC-N - - - - - - - - - - - - - - - - - - ● ● ● ● ● 
EPIC-NL - - -  ●  ● ●  ●  ● ●  ●  ● ● ● ●  ● ● 
ET2DS ● ● ● ● ● ● - - ● ● ● - - ● ● - - ● ● - - 
FHS ●  ● ●  ● ●  ● ●  ● ●  
HAPIEE-CZ ●   ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●  ● ● 
HAPIEE-LT ●   ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●  ● ● 
HAPIEE-PL ●   ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●  ● ● 
HAPIEE-RU ●   ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●  ● ● 
HIFMECH ● ● ● ● - - ● ● - - ●  - - ●  - - 
IMPROVE n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
InCHIANTI - - - - - - - - - - - - - - - - - - - - - - - 
ISGS-SWISS ●   ●  - - ●  - - ● ● ●  - - - - - 
MedStar - - - - - - - - ● ● - - - - - - - - - - - - 
MESA ●   ●    ●    ●    ●    
MRC Fenland - GWAS  - - - - - - - - - - - - - - - - - - - - - - - 
MRC Fenland -Metabochip - - - - - - - - - - - - - - - - - - - - - - - 
MRC NSHD - - - - - - - - - - - - - - - - - - - - - - - 
NPHS-II ●  ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 
PREVEND ●  ● ● ● ● ● ● ● ● ● ● ● ● 
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PROSPER - ● ● - ● ● ● ● - ● ● ● ● - ● ● ● ● - ● ● ● ● 
SMART - - - - - - - - - - - - - - - - - - - - - - - 
TPT ●  ● ●  ● ●  ● ●  ● ●  
UCP - - - - - - - - ●   - - - - - - - - - - 
UDACS - - - ● ● - - ● ● - - ● ● - - ● ● - - 
WHI ●   ●    ●    ●    ●    
Whitehall II ●  ● - - ● - - ● - - ● ●   
16
 Supplementary Table 4 - Published associations of IL6R variants with biomarkers and non-cardiovascular outcomes 
 
 
Endpoint Source GWAS SNP (minor allele)  Cases/controls (studies) LD with rs7529229 (r2)c Odds ratio (95% CI) p-value 
        
All cancer Present studies No rs75299229 (T) 3,828/40,006(10) - 0.98 (0.93 to 1.03) 0.39 
 Published 59 No rs8192284 (C) 1,548/17,117 (1) 0.97 1.05 (0.95 to 1.16) 0.38 
 Pooled estimate   5,376/57,123 (11) - 0.99 (0.95 to 1.04) 0.66 
        
Breast cancer Present analysis Yes rs4537545 (A) 13,574/14,852 (1) 1.00 1.01 (0.94 to 1.10) 0.74 
 Published 60 Yes rs4537545(A) 2,702/5,726 (1) 1.00 0.97 (0.90 to 1.05) 0.50a 
 Pooled estimate   14,456/15,758 (2) - 1.03 (0.96 to 1.10) 0.40 
        
Respiratory infection Published 61 No rs8192284 (C) 264/287 0.97  0.19b 
        
        
Colorectal cancer Present analysis No rs4537545 (A) 1863/1903 (2) 1.00 1.03 (0.96 to 1.12) 0.40 
 
p-value thresholds for declaration of significance: a 1x10-6; b 0.05; 
* Discovery dataset 
†Replication dataset 
c LD data from 1000 Genomes Pilot 1, assessed using SNP Association and Proxy Search tool (http:// http://www.broadinstitute.org/mpg/snap/, accessed 26 June 2011) 
  
17
 Supplementary Table 5 - Genotyping platforms and QC metrics, genotype frequency across studies 
Study Participants Genotyping platform Call rate (%) 
Proxy SNP used  
 (LD with rs7529229, 
r2)* 
TT (wildtype 
homozygotes) TC 
CC (variant 
homozygotes) 
MAF 
(%) Hardy-Weinberg 
χ2 p=value 
AAA 2,359  KASP?? 96 - 771 1,128 369 41.1 1.65 0.199 
ARIC 9,588  IBC Cardiochip 100 - 3,316 4,571 1,701 41.6 3.34 0.067 
BRHS 3,945  KASPar 98 - 1,270 1,889 715 42.8 0.07 0.787 
BWHHS 3,445  IBC Cardiochip 100 - 1,143 1,696 600 42.1 0.46 0.498 
CaPS 1,404 KASPar 98 - 479 688 267 41.4 0.14 0.706 
CARDIA 1,443  IBC Cardiochip 100 - 500 711 231 40.7 0.68 0.410 
CFS 135  IBC Cardiochip 100 - 47 55 33 44.8 4.20 0.040 
CHS 3,952  IBC Cardiochip 100 - 1,400 1,895 656 40.6 0.12 0.730 
EAS 917  ABI TaqMan 97 - 314 405 171 42.0 3.85 0.050 
EDS 319 ABI TaqMan 100 rs8192284 (0.97) 127 147 45 37.21 0.06 0.814 
ELSA 5,504  KASPar 99 - 1,807 2,646 1,015 42.8 0.72 0.397 
Ely 1,601  Metabochip 100 rs4129267 (1.00) 536 765 300 42.6 0.86 0.35 
EPIC-N 1,690 Metabochip 100 rs4129267 (1.00) 588 791 311              42.0 2.45 0.12 
EPIC-NL 5,194  IBC Cardiochip 97 - 1,916 2,457 821 39.5 0.51 0.475 
ET2DS 1,069  KASPar 99 - 369 512 172 40.61 0.06 0.802 
FHS 1,336  IBC Cardiochip 100 - 469 647 220 40.7 0.02 0.901 
HAPIEE-CZ 6,700 KASPar 98 - 2,545 3,146 1,009 38.5 0.52 0.47 
HAPIEE-LT 6,914 KASPar 99 - 3,106 3,073 735 32.9 0.38 0.54 
HAPIEE-PL 8,758 KASPar 99 - 3,399 4,063 1,296 38.0 2.08 0.15 
HAPIEE-RU 7,085 KASPar 98 - 3,176 3,111 798 33.2 0.75 0.39 
HIFMECH 1,096  ABI TaqMan 97 - 381 477 204 41.72 6.14 0.013 
IMPROVE 3,465 Metabochip n/a rs7518199 (0.97) 1,377 1,621 467 36.9 0.09 0.77 
InCHIANTI 1,199 Illumina 550k >98 rs4129267 (1.00) 457 589 164 37.9 1.42 0.23 
ISGS-SWISS 2,558 Illumina 500K v1/3 & 610/660K >95 - 888 1,261 409 41.0 1.21 0.271 
MedStar 851  Affymetrix 6.0 >95 - 321 412 118 38.1 0.61 0.44 
MESA 2,298  IBC Cardiochip 100 - 743 1,143 412 42.8 0.58 0.447 
MRC Fenland - GWAS  1,376  Affymetrix 500K 100 rs4537545 (1.00) 465 683 227 41.4 0.80 0.37 
MRC Fenland - Metabochip 3,059  Metabochip 100 rs4129267 (1.00) 1,067 1,481 511 40.9 0.006 0.94 
MRC NSHD 2,402  KASPar 100 - 806 1,139 457 42.7 2.33 0.127 
NPHS-II 2,755  ABI TaqMan 97 - 940 1,219 508 41.9 10.00 0.002 
PREVEND 3,876  KASPar 100 - 1,365 1,869 633 40.5 0.03 0.87 
18
 MAF - minor allele frequency 
*Linkage disequilibrium (LD) data derived from 1000 Genomes Pilot 1 
1 Minor allele frequency in diabetes cases 
2 Minor allele frequency in CHD cases 
 
  
PROSPER 5,244  Illumina 660K 100 rs4537545 (1.00) 1,842 2,532 869 40.7 0.00 0.982 
SMART 8,026 KASPar >95 - 3,129 3,944 1,260 38.8 0.09 0.77 
TPT 4,114 ABI TaqMan 92 - 1284 1852 638 41.4 0.46 0.50 
UCP 1,632 IBC Cardiochip 100 - 583 788 261 40.1 0.04 0.85 
UDACS 585 ABI TaqMan 100 rs8192284 (0.97) 127 147 45 37.21 0.06 0.81 
WHI 5,723  IBC Cardiochip 100 - 1931 2771 1010 41.9 0.09 0.770 
Whitehall II 5,059  IBC Cardiochip 100 - 1710 2451 881 41.8 0.00 0.957 
19
  
Supplementary Table 6 - SNPs within 55kb of IL6R on the Cardiochip platform and their associations with log IL-6 in the Whitehall II study 
 Association with log-IL-6 
Selected for analysis SNP Chr. Base pair position No. of participants β-coefficient (SE) 95% Confidence interval Regression model p-value 
 rs7518199 1 152674043 4475 0.089 (0.012) 0.064 to 0.113 1.52x10-12 
 rs4129267 1 152692888 4473 0.088 (0.012) 0.064 to 0.113 1.77 x10-12 
 rs4537545 1 152685503 4472 0.087 (0.012) 0.063 to 0.112 2.73 x10-12 
 rs7529229 1 152687402 4472 0.086 (0.012) 0.061 to 0.110 6.15 x10-12 
 rs12740969 1 152753684 4479 -0.078 (0.013) -0.103 to -0.052 2.20 x10-09 
 rs4553185 1 152677579 4469 -0.064 (0.012) -0.088 to -0.039 3.22 x10-07 
 rs4845371 1 152674964 4462 -0.062 (0.013) -0.087 to -0.038 6.78 x10-07 
 rs4509570 1 152703008 4476 -0.073 (0.015) -0.102 to -0.044 7.17 x10-07 
 rs4845625 1 152688691 4473 -0.062 (0.012) -0.086 to -0.037 7.92 x10-07 
 rs28638007 1 152687978 4485 -0.061 (0.012) -0.086 to -0.037 8.57 x10-07 
 rs7553796 1 152671030 4458 -0.061 (0.013) -0.086 to -0.037 9.64 x10-07 
 rs6667434 1 152675724 4476 -0.060 (0.013) -0.085 to -0.036 1.55 x10-06 
 rs4845618 1 152666639 4470 -0.055 (0.012) -0.080 to -0.031 9.26 x10-06 
 rs4845626 1 152690109 4486 -0.045 (0.016) -0.078 to -0.013 0.006 
 rs4845374 1 152693571 4484 -0.046 (0.017) -0.079 to -0.013 0.006 
 rs8192282 1 152668303 4488 -0.046 (0.017) -0.079 to -0.013 0.007 
 rs11804305 1 152691121 4486 -0.046 (0.017) -0.079 to -0.013 0.007 
 rs4329505 1 152699044 4481 -0.044 (0.017) -0.077 to -0.011 0.009 
 rs10159236 1 152698029 4486 -0.043 (0.017) -0.076 to -0.010 0.010 
 rs12083537 1 152647727 4475 0.035 (0.015) 0.005 to 0.065 0.021 
 rs7411976 1 152649067 4481 0.103 (0.047) 0.010 to 0.196 0.029 
 rs1386821 1 152648673 4480 0.028 (0.016) -0.003 to 0.059 0.073 
 rs2229237 1 152668420 4489 -0.068 (0.066) -0.197 to 0.060 0.298 
 rs1552481 1 152642977 4488 0.285 (0.338) -0.378 to 0.948 0.399 
 rs6427641 1 152647110 4479 0.007 (0.012) -0.017 to 0.032 0.572 
 rs12089132 1 152644960 4489 0.284 (0.586) -0.865 to 1.432 0.628 
 rs3887104 1 152643295 4477 -0.008 (0.016) -0.040 to 0.024 0.640 
 rs4075015 1 152655820 4465 -0.006 (0.013) -0.031 to 0.019 0.643 
 rs12096944 1 152663782 4487 0.104 (0.239) -0.365 to 0.573 0.663 
 rs4601580 1 152661041 4481 -0.003 (0.012) -0.027 to 0.022 0.819 
 rs12739228 1 152692814 4489 -0.007 (0.033) -0.072 to 0.058 0.838 
 rs1552482 1 152642862 4489 0.062 (0.338) -0.601 to 0.726 0.853 
 rs11265610 1 152647408 4487 0.062 (0.338) -0.601 to 0.725 0.854 
 rs28730735 1 152693656 4486 -0.016 (0.115) -0.242 to 0.210 0.892 
 rs4845617 1 152644522 4452 -0.001 (0.013) -0.026 to 0.024 0.948 
 rs2054855 1 152637562 4478 0.001 (0.018) -0.035 to 0.037 0.957 
 rs34099703 1 152668336 4489 -0.026 (0.586) -1.175 to 1.122 0.964 
 rs4845616* 1 152644193 4488 - - - 
20
  rs4845615* 1 152641901 4489 - - - 
 rs28730736* 1 152693674 4487 - - - 
 rs7537306* 1 152667629 4489 - - - 
 rs28730732* 1 152668229 4463 - - - 
SNPs are ranked on p-value and β-coefficient; β-coefficients are reported on the log scale. 
*There was no variation in genotype at these very  rare SNPs in the Whitehall II study sample and consequently a regression model could not be fitted. 
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 Supplementary Table 7 - Safety endpoints in trials of tocilizumab therapy 
Endpoint(s)* No. of RCTs No. randomised No. of events Odds ratio (95%CI)† P I2 (%) 
CARDIAC    
Myocardial infarction 1 335 1 0.30 (0.01, 7.49) 0.47 - 
 Cardiac 1 410 2 0.99 (0.06, 15.94) 0.99 - 
 Serious cardiac 2 1629 6 1.31 (0.23, 7.42) 0.76 0 
 Hypertension 2 1629 70 1.41 (0.83, 2.39) 0.20 18.5 
VASCULAR   
 Vascular 3 1965 120 1.34 (0.90, 1.99) 0.15 0 
DEATH   
 Death 2 2346 8 1.86 (0.45, 7.60) 0.39 63.8 
NERVOUS SYSTEM   
 Nervous system 3 1964 245 1.26 (0.95, 1.68) 0.10 0 
 Serious nervous system 2 1629 10 1.40 (0.35, 5.53) 0.63 0 
RESPIRATORY   
 Serious respiratory 2 744 43 0.96 (0.51, 1.79) 0.89 0 
INFECTION   
 Infection and infestation 3 1964 705 1.30 (1.07, 1.58) 0.008 0 
 Upper respiratory tract infection 2 534 37 1.20 (0.61, 2.34) 0.60 0 
 Pneumonia 2 2019 9 0.87 (0.23, 3.29) 0.84 0 
 Serious infection 5 2854 70 2.29 (1.33, 3.92) 0.003 12.2 
IMMUNOSUPPRESSION   
 Grade 3 neutropenia (0.5 to <1.0 × 109/L) 3 2346 51 26.00 (5.02, 134.70) 9.34 X 10-6 0 
NEOPLASIA   
 Neoplasia 2 1200 4 0.42 (0.06, 2.88) 0.38 0 
LIPIDS    
 Total cholesterol >6.2mmol/L or >240mg/dL 3 2420 391 4.87 (3.64, 6.51) 1.74 x 10-26 0 
 HDL-C >+30% or >60mg/dL or 1.6mmol/L 4 2755 319 2.46 (1.88, 3.22) 5.06 x 10-11 67.7 
 LDL >160mg/dL or >4.1mmol/L 3 2346 255 5.11 (3.52, 7.41) 7.18 x10-18 0 
 LDL:HDL lipoprotein index >30%↑ 2 1555 266 1.97 (1.46, 2.67) 9.34 x 10-6 0 
 Triglycerides >500mg/dL or >5.7mmol/L 1 1220 15 1.42 (0.45, 4.50) 0.55 - 
 ApoB:ApoA1 atherogenic index >30%↑ 2 1555 150 1.26 (0.88, 1.81) 0.21 0 
HEPATIC ENZYMES   
 ALT >3x ULN 4 2755 94 6.96 (3.58, 13.50) 9.95 x 10-9 0 
 AST >3u ULN 3 2420 30 4.75 (1.66, 13.62) 0.004 0 
22
  
* Endpoint(s) definitions. Cardiac: Smolen62 - not defined. Serious cardiac: Smolen – not defined; Genovese63 – not defined. Vascular: Emery64 – not defined; Smolen – not defined; 
Genovese – not defined. Nervous system: Genovese – not defined; Smolen – not defined; Emery – not defined. Serious nervous system: Genovese – not defined; Smolen – not defined. 
Infection and infestation: Genovese – not formally defined, including upper respiratory tract infections, skin and subcutaneous tissue infections; Emery – not defined; Smolen – not defined. 
Serious infection: Maini – not formally defined, including arthritis and 2 cases of sepsis; Kremer 65- not formally defined, including lower respiratory tract and gastrointestinal infections; 
Genovese - not formally defined, including staphylococcal cellulitis, acute pyelonephritis, sepsis and pneumonia; Smolen – not formally defined, including urinary tract infection, pneumonia, 
cellulitis, peridiverticular abscess and upper respiratory tract infection; Emery - not formally defined, including staphylococcal polyarthritis, cellulitis, necrotising pneumonia, urosepsis, 
osteomyelitis. Serious respiratory: Smolen – not formally defined, including idiopathic pulmonary fibrosis; Emery – not defined. Neoplasia: Smolen – not defined; Kremer: solid malignancy 
in TCZ group (uterine cancer, n=1), solid malignancy in placebo group (breast cancer n=1).  
 
† Pooled using Mantel-Haenszel fixed effects models  
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 Supplementary Table 8 - Associations of the functional IL6R rs8192284 variant with IL-6, CRP and fibrinogen concentrations in the Whitehall II study 
 Whitehall II 
Biomarker n % difference in geometric mean per minor allele (95% CI) 
   
IL-6 4,480 9.26 (6.62 to 11.96) 
CRP 4,503 -9.35 (-13.66 to -4.83) 
Fibrinogen 4,466 -0.87 (-1.79 to 0.06) 
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 Supplementary Figures 
1 - Mechanisms of IL-6 receptor production, IL-6 signalling and inhibition of the IL-6 receptor by tocilizumab 
2 - Linkage disequlibrium and disease/biomarker associated SNPs in and around IL6R (1q21.3) 
3 - Identification of publications contributing to the systematic review of trials of tocilizumab treatment 
4 - Mean difference in CRP at 4 and 8mg/kg doses of tocilizumab at 4, 8 and 16 weeks of therapy 
5 - Box and whisker plots illustrating summary values for the main inflammation and lipid markers evaluated 
6 - Stratified associations of IL6R rs7529229 variant on (a) IL-6, (b) CRP, and (c) fibrinogen concentrations  
7 - Association of IL6R rs7529229 with log CRP levels stratified by genotyping platform used in each study contributing to the 
analysis 
8 - Association of the IL6R SNPs a. rs4845371 and b. rs12740969 with IL-6, CRP and fibrinogen concentration 
9 - Stratified associations of IL6R rs7529229 with fatal and non-fatal coronary heart disease 
10 - Association of IL6R rs7529229 with risk of CHD (fatal & non-fatal) stratified by genotyping platform used in each study 
contributing to the analysis 
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Supplementary Figure 1 - Mechanisms of IL-6 receptor production, IL-6 signalling and inhibition of the IL-6 receptor by 
tocilizumab
a. Production of soluble IL-6 receptor (sIL-6R) is influenced by Asp358Ala (rs8192284, tagged by rs7529229) variant in IL6R.  
Proteolytic cleavage of the mIL-6R is increased with carriage of the Ala allele resulting in greater soluble concentration of the soluble 
receptor and reduced numbers of functioning mIL-6R. Both classical (through the membrane-bound IL-6R) and trans-signalling (through 
the soluble IL-6R) pathways are active with either allele, however the preferential production of sIL-6R with the Ala allele results in 
increased trans-signalling and reduced classical signalling.  The phenotypic effects associated with the Ala allele (and the minor allele at 
rs7529229) are consequences of this alteration in receptor production.
b. Tocilizumab blocks both the mIL-6R and the sIL-6R, inhibiting IL-6 signalling via both classical and trans-signalling pathways.
c. Comparison between the directions of effects of the IL6R variant and tocilizumab reflect the similarities and differences in the 
biological processes of the two scenarios.
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Supplementary Figure 2 - Linkage disequlibrium and disease/biomarker associated SNPs in and around IL6R (ch1q21.3)
a. (left panel) SNPs on chromosome 1q21.3 in the vicinity of IL6R based on HapMap Phase 3 build 36.  
b. (centre panel) Prior disease and biomarker associations
c. (right panel) Linkage disequilibrium (r2) for SNPs contributing to the current analysis
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Supplementary Figure 3 - Identification of publications contributing to the systematic review of trials of tocilizumab treatment
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
 
PRISMA 2009 Flow Diagram
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Supplementary Figure 4 - Mean difference in CRP at 4, 8 and 16 mg/kg doses of tocilizumab at 4-12 weeks of therapy
Data pooled from randomised trials of tocilizumab versus placebo in patients with rheumatoid arthritis and observational studies of 
tocilizumab therapy.
29
Supplementary Figure 5 - Box and whisker plots illustrating summary values for the main inflammation and lipid markers 
evaluated.  
Plots show median (horizontal bar), interquartile range (box) and minimum/maximum (whiskers).
a
b
c
30
Supplementary Figure 5 continued
d
e
f
31
Supplementary Figure 5 continued
g
h
i
32
Supplementary Figure 5 continued
i
33
Supplementary Figure 6 - Stratified associations of IL6R rs7529229 variant on (a) IL-6, (b) CRP, and (c) fibrinogen 
concentrations. 
Associations are stratified by age, prevalent CHD or diabetes status, Framingham score and non-HDL levels.
a
34
Supplementary Figure 6 continued
b
35
cSupplementary Figure 6 continued
36
Supplementary Figure 7 - Association of IL6R rs7529229 with log CRP levels stratified by genotyping platform used in each 
study contributing to the analysis 37
Supplementary Figure 8 - Association of the IL6R SNPs a. rs4845371 and b. rs12740969 with IL-6, CRP and fibrinogen 
concentration.  
Estimates are based on pairwise comparison of individuals heterozygous or homozygous for the variant allele with reference to the 
wildtype homozygous group.  The total number of participants (studies) is also shown.
a
38
Supplementary Figure 8 continued
b
39
Supplementary Figure 9 - Stratified associations of IL6R rs7529229 with fatal and non-fatal coronary heart disease.
Estimates are stratified by participant age, sex, the presence of CVD or diabetes at baseline, BMI, estimated risk of CVD based on the 
Framingham equation and by tertile of non-HDL-C and log CRP.  The p-value from a chi-squared test of heterogeneity is also presented.
40
Supplementary Figure 10 - Association of IL6R rs7529229 with risk of CHD (fatal & non-fatal) stratified by genotyping platform 
used in each study contributing to the analysis 41
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